Literature DB >> 7547013

Reversible ischaemia in hypertrophic cardiomyopathy.

H Thomson1, W Fong, W Stafford, M Frenneaux.   

Abstract

Atypical and typical chest pains are common symptoms in patients with hypertrophic cardiomyopathy. Some of these chest pains seem to be caused by ischaemia. It is difficult to objectively demonstrate ischaemia in hypertrophic cardiomyopathy. The first line treatment for chest pain considered to be ischaemic in patients with hypertrophic cardiomyopathy is the use of either a beta blocker or calcium blocker. Septal myectomy can be effective in patients with symptoms refractory to conventional treatment but is associated with significant morbidity and mortality. Recently dual chamber pacing has been advocated in such patients. In some cases dual chamber pacing alleviates chest pain in hypertrophic cardiomyopathy by an anti-ischaemic action, presumably by reducing the left ventricular outflow tract gradient and perhaps by causing an associated decrease in left ventricular outflow tract gradient and perhaps by causing an associated decrease in left ventricular end diastolic pressure.

Entities:  

Mesh:

Year:  1995        PMID: 7547013      PMCID: PMC484009          DOI: 10.1136/hrt.74.3.220

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  20 in total

1.  Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy.

Authors:  P J Hubner; G M Ziady; G K Lane; T Hardarson; B Scales; C M Oakley; J F Goodwin
Journal:  Br Heart J       Date:  1973-11

2.  Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history.

Authors:  S Frank; E Braunwald
Journal:  Circulation       Date:  1968-05       Impact factor: 29.690

3.  Surgical resection in idiopathic hypertrophic subaortic stenosis with a combined approach through aorta and left ventricle.

Authors:  T M Agnew; B G Barratt-Boyes; P W Brandt; A H Roche; J B Lowe; K P O'Brien
Journal:  J Thorac Cardiovasc Surg       Date:  1977-08       Impact factor: 5.209

4.  Angina in idiopathic hypertrophic subaortic stenosis. A clinical correlate of regional left ventricular dysfunction: a videometric and echocardiographic study.

Authors:  M G Sutton; A J Tajik; H C Smith; E L Ritman
Journal:  Circulation       Date:  1980-03       Impact factor: 29.690

5.  The natural history of left ventricular hypertrophy in hypertrophic cardiomyopathy: an electrocardiographic study.

Authors:  W J McKenna; M Borggrefe; D England; J Deanfield; C M Oakley; J F Goodwin
Journal:  Circulation       Date:  1982-12       Impact factor: 29.690

6.  The pathophysiology and diverse etiology of septal perforator compression.

Authors:  J B Kostis; A E Moreyra; N Natarajan; M Hosler; P T Kuo; H L Conn
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

7.  Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy.

Authors:  V Dilsizian; R O Bonow; S E Epstein; L Fananapazir
Journal:  J Am Coll Cardiol       Date:  1993-09       Impact factor: 24.094

8.  Assessment of chest pain in hypertrophic cardiomyopathy using exercise thallium-201 myocardial scintigraphy.

Authors:  D Pitcher; R Wainwright; M Maisey; P Curry; E Sowton
Journal:  Br Heart J       Date:  1980-12

9.  Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries.

Authors:  B J Maron; S E Epstein; W C Roberts
Journal:  Am J Cardiol       Date:  1979-06       Impact factor: 2.778

10.  Left ventricular relaxation and filling in hypertrophic cardiomyopathy. An echocardiographic study.

Authors:  J E Sanderson; T A Traill; M G Sutton; D J Brown; D G Gibson; J F Goodwin
Journal:  Br Heart J       Date:  1978-06
View more
  1 in total

1.  Effects of permanent dual chamber pacing on myocardial perfusion in symptomatic hypertrophic cardiomyopathy.

Authors:  J L Posma; P K Blanksma; E E Van Der Wall; W Vaalburg; H J Crijns; K I Lie
Journal:  Heart       Date:  1996-10       Impact factor: 5.994

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.